Regeneron provides initial data on two candidate antibodies ...

Despite the availability of different classes of analgesics, millions of Americans continue to suffer from moderate to severe pain due to a variety of medical conditions , which is designed to block pain sensitization in the neurons. The efficacy and safety of REGN475 are evaluated in several Phase 2 studies in the parameters of short-term pain, both in the treatment of moderate to severe pain caused by osteoarthritis.Regeneron will provide further updates and clinical enterprise to its first Investor Day in New York on July 15.

remains the leading cause of death in the United States for men and women and is a leading cause of death in the developed world. However, despite the relatively large LDL cholesterol-lowering therapies, including the statin class of agents, coronary artery disease remains a major cause of morbidity and mortality. REGN727 is a fully human monoclonal antibody designed to reduce LDL cholesterol through a new robust mechanism of action. REGN727 designed to inhibit PCSK9, which results in the prevention of degradation of LDL receptors in the liver and facilitates the clearance of LDL from the systemic circulation, reducing levels of LDL in the blood.

Amitriptyline, a tricyclic antidepressant introduced in 1960, and other tricyclic antidepressants are supposed to exert their effects by increasing levels of chemical messenger, serotonin and norepinephrine in the brain.

Regeneron is a biopharmaceutical company that integrated research, develops and commercializes drugs to treat serious medical conditions. In addition to ARCALYST Injection for Subcutaneous Use, its first commercialized product, Regeneron therapeutic candidates in clinical trials to phase 3 for the potential treatment of diseases of the eye , and certain cancers. Other therapeutic candidates are in early stage development programs and other inflammatory conditions, pain, cholesterol reduction, immune and allergic conditions and cancer.

This press release provides historical information and includes forward-looking statements about Regeneron and its products, development programs, finance and business, involving a number of risks and uncertainties. These include, among others, risks and time associated with preclinical and clinical development of Regeneron drug candidates, the decisions taken by administrative bodies and government that may delay or restrict our ability to continue to develop or market its products and medicines candidates, competing drugs that are superior to Regeneron product candidates and drug use , the uncertainty of acceptance Regeneron?s product and market drug candidates, unanticipated expenses, the availability and cost of capital, cost of product development, production and sales, the potential for any collaboration agreement, including Regeneron agreements with the sanofi-aventis Group and Bayer HealthCare, be canceled or terminated without any product success and the risks associated with third countries, intellectual property. A more complete description of these risks and others can be found in Regeneron?s filings with the U. Securities and Exchange Commission , including its Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter end March 31, 2010. Regeneron has no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

?We are extremely pleased with the productivity of our antibody collaboration with sanofi-aventis, and progression of NGF and PCSK9 antibodies, in particular,? said Leonard S. Schleifer, MD, Ph.D., President and Chief Administrator.

REGN727 and REGN475 Both are developed to address areas of need health are important and represent important news for our clinical pipeline. ?

Source: http://www.whitmoremansion.com/regeneron-provides-initial-data-on-two-candidate-antibodies.html

acm awards 2012 january jones ncaa final game miranda lambert reba mcentire acm awards luke bryan